Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00901537 · ClinicalTrials.gov registry record · Phase 1
Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer
A Phase 1 study, sponsored by Loma Linda University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00901537: Clinical Trial Phase 1 study, sponsored by Loma Linda University.
NCT00901537 is a Phase 1 study that was terminated before completion, run by Loma Linda University. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00901537, a Phase 1 study, was terminated before completion, sponsored by Loma Linda University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The standard of care for head and neck and lung cancer includes chemotherapy, radiation and surgery. For patients with cancer of head and neck or lung that recurs after surgery and/or radiation, or has spread to other parts of body, chemotherapy using cisplatin can slow down tumor growth and extend lifespan. The study drug, azacitidine, can block the ability of some cancer cells to replicate, and has been approved by the Food and Drug Administration for use in myelodysplastic syndrome, which is a slowly developing blood cell-related cancer. In laboratory and animal experiments using head and neck and lung cancer cells, azacitidine has been shown to be a cisplatin "helper", (that is, it makes cisplatin more effective in stopping the growth of head and neck and lung cancer. ) Since the combination of azacitidine and cisplatin has not been used in patients with head and neck or lung cancer, the investigators are performing this study combining azacitidine and cisplatin to find out what effects, good and/or bad, the study drug may have on patients with advanced head and neck or lung cancer. The investigators are doing this study because they would like to find a better treatment for these types of cancer.
Interventions
- DRUG Azacitidine and Cisplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2009-02 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Why NCT00901537 stopped before completion
NCT00901537 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which Azacitidine and Cisplatin is the first listed.
NCT00901537 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00901537 about?
NCT00901537 is a clinical study titled "Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer". The standard of care for head and neck and lung cancer includes chemotherapy, radiation and surgery. For patients with cancer of head and neck or lung that recurs after surgery and/or radiation, or has spread to other parts of body, chemotherapy using cisplatin can slow down tumor growth and extend ...
What is the current status of trial NCT00901537?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2009-02. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00901537?
The interventions under investigation include: Azacitidine and Cisplatin (DRUG).
Who is sponsoring clinical trial NCT00901537?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00901537's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia